This report was first published by Endpoints News. To see the original version, click here
Altesa BioSciences has closed a $75 million Series B, enough to finance a Phase 2b study of its oral respiratory drug meant to prevent serious COPD exacerbations.
The raise announced Thursday adds fresh capital for the Atlanta biotech, which is helmed by Brett Giroir, a former HHS official during the first Trump administration. The round was led by Forbion, with participation from Sanofi and previous investors.
您已阅读20%（503字），剩余80%（1974字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。